Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...
Nearly two years after going live in Europe, the latest version of Abbott’s FreeStyle Libre continuous glucose monitor is ready to make its stateside debut. The FDA cleared the FreeStyle Libre 3 ...
The system was the first to allow people with diabetes to monitor blood glucose without fingersticks. Abbott’s 14-day Freestyle Libre continuous glucose monitor (CGM) has been approved by the FDA, ...
Abbott has secured a European approval for the newest generation of its FreeStyle Libre continuous glucose monitor—which the company describes as the world’s smallest and thinnest diabetes sensor, ...
MISSISSAUGA, ON, July 8, 2025 /CNW/ -- Abbott (NYSE: ABT) today announced that its latest generation of sensor-based glucose monitoring technology, the FreeStyle Libre 3 Plus * sensor, is now ...
Tandem Diabetes Care (TNDM) begins global commercial rollout of t:slim X2 pump integration with the FreeStyle Libre 3 Plus CGM sensor, expanding choice and personalization for people living with ...
Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...
In a seemingly ongoing supply issue with FreeStyle Libre sensors, people with type 1 diabetes are struggling to get hold of replacement sensors for the blood glucose monitor. Pharmacy teams and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback